Identification of a Unique cyp51A Mutation in Aspergillus fumigatus from a Patient with Systemic Lupus Erythematosus and Limited Systemic Sclerosis: The First Report of Acquired Azole Resistance in Colombia - Summary - MDSpire
Advertisement
Identification of a Unique cyp51A Mutation in Aspergillus fumigatus from a Patient with Systemic Lupus Erythematosus and Limited Systemic Sclerosis: The First Report of Acquired Azole Resistance in Colombia
To report a case of acquired azole resistance in Aspergillus fumigatus in a patient with systemic lupus erythematosus and limited systemic sclerosis in Colombia, highlighting its clinical significance.
Key Findings:
The patient developed invasive aspergillosis caused by a voriconazole-resistant A. fumigatus strain, underscoring the need for vigilance in treatment.
The identified cyp51A gene variant TR46/F46Y/Y121F/M172V/E427K contributes to the understanding of azole resistance mechanisms and its clinical implications.
This case represents the first report of acquired azole resistance in Colombia, emphasizing the need for awareness in clinical practice.
Interpretation:
The emergence of azole-resistant A. fumigatus in Colombia highlights the urgent need for improved antifungal susceptibility testing and surveillance in clinical settings to prevent similar cases.
Limitations:
Antifungal susceptibility testing was not routinely performed during the patient's treatment, which could have informed better management.
The prevalence of azole resistance in Colombia remains largely unknown due to limited surveillance, posing a risk to public health.
Conclusion:
This case underscores the importance of monitoring antifungal resistance in immunocompromised patients and the need for tailored treatment strategies to improve patient outcomes.
by Carlos Morales-Pertuz, Miguel Ángel Vanegas, Ximena Castañeda-Luquerna, Eliana Maldonado, Jorge Alberto Carrillo, Anghie Katherine López-Valencia, Carolina Firacative
